{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-25-000082","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.480284+00:00","generated_at":"2026-05-23T05:04:49.114346+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Azenosertib shows RB1 loss sensitivity in SCLC/TNBC; cfDNA MR predicts HGSOC response","bullets":["Preclinical: RB1 loss sensitizes TP53-mutant SCLC/TNBC cells; in vivo TGI 90% in RB1-mutant vs 49% in WT xenografts (Ex-99.1).","Clinical (N=123 HGSOC): cfDNA TP53 molecular response (MR) predicts RECIST response; MR+ median TTP 5.49 vs 2.69 months for MR- (HR 0.43, p<0.0001).","Complete MR (mCR) yields 6.5-month median TTP; MR precedes RECIST by 14 weeks for responders and 8 weeks for progressors (Ex-99.2).","Azenosertib shows synergistic activity with encorafenib + cetuximab in BRAF V600E preclinical models (Ex-99.4)."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-25-000082","json":"https://secwatch.observer/filing/0001725160-25-000082.json","markdown":"https://secwatch.observer/filing/0001725160-25-000082.md","text":"https://secwatch.observer/filing/0001725160-25-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000082/0001725160-25-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000082/zntl-20250427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:04:49.114346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}